Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.608 GBX | -1.29% | +0.50% | -30.09% |
Feb. 29 | Hemogenyx Pharmaceuticals raises money for leukaemia treatment | AN |
Feb. 29 | Hemogenyx Pharmaceuticals Raises $4.2 Million via Share Placing | MT |
Financials (USD)
Sales 2021 | - | Sales 2022 | - | Capitalization | 12.98M |
---|---|---|---|---|---|
Net income 2021 | -5M | Net income 2022 | -3M | EV / Sales 2021 | - |
Net cash position 2021 | 6.83M | Net Debt 2022 | 890K | EV / Sales 2022 | - |
P/E ratio 2021 |
-2.85
x | P/E ratio 2022 |
-3.26
x | Employees | 14 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.27% |
1 day | -1.29% | ||
1 week | +0.50% | ||
Current month | -8.64% | ||
1 month | -5.96% | ||
3 months | -44.55% | ||
6 months | -21.56% | ||
Current year | -30.09% |
Managers | Title | Age | Since |
---|---|---|---|
Alexis Sandler
FOU | Founder | - | 12-12-31 |
Founder | 59 | 12-12-31 | |
van Besien Koen
CTO | Chief Tech/Sci/R&D Officer | - | 22-08-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Redmond
BRD | Director/Board Member | 76 | - |
Marc Feldmann
CHM | Chairman | 79 | 18-04-08 |
Founder | 59 | 12-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 1.608 | -1.29% | 5,063,450 |
24-04-23 | 1.629 | +0.87% | 4,149,071 |
24-04-22 | 1.615 | -1.58% | 5,660,865 |
24-04-19 | 1.641 | -1.80% | 5,990,463 |
24-04-18 | 1.671 | +4.44% | 12,610,160 |
Delayed Quote London S.E., April 24, 2024 at 11:35 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-30.09% | 27.19M | |
-1.51% | 105B | |
+3.22% | 97.5B | |
+1.86% | 22.19B | |
-16.53% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.09% | 14.52B | |
+5.47% | 14.09B | |
+28.85% | 10.99B |
- Stock Market
- Equities
- SILF Stock